Leighanne Oh joined Novo Growth in 2022 and brings with her private and public investing experience and an operating background. Before joining us, Leighanne started her investing career at SoBE Bioequities (Sofinnova’s L/S hedge fund) where she focused on public investments in global biotech and pharmaceutical companies. She served on Sofinnova’s investment committee as a private investor focused on clinical stage investments from 2019 – 2022. Prior to that, Leighanne began her career as an Analyst on the Healthcare Investment Banking team at Jefferies. In that role, she focused on M&A, public and private capital raising, licensing deals, and a wide scope of advisory work for biotechnology and pharmaceutical companies. Trained as a protein and biomedical engineer, Leighanne also brings her operating background as a manufacturing engineer from GE Healthcare.
Leighanne holds a M.S. and B.S.E. in Biomedical Engineering from Duke University and is a Gates Millennium Scholar.